Compass Therapeutics Inc. (CMPX)
Healthcare
Biotechnology
1.90 $
-1.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Compass Therapeutics Inc. (CMPX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 68.1% of the shares are freely tradable; institutional investors hold 94.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
94.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
12.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
68.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
26.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
180Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.32 | 16,790,809 | +0.0 | 03/31/2026 |
| Orbimed Advisors, LLC | 8.45 | 15,219,994 | +0.0 | 03/31/2026 |
| Suvretta Capital Management, LLC | 7.94 | 14,307,379 | +0.9 | 03/31/2026 |
| Vivo Capital, LLC | 5.30 | 9,545,466 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.28 | 9,506,080 | +1.3 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 4.71 | 8,486,500 | +91.3 | 03/31/2026 |
| Enavate Sciences GP, LLC | 4.32 | 7,788,150 | +0.0 | 03/31/2026 |
| Bvf Inc | 4.31 | 7,764,842 | +0.0 | 03/31/2026 |
| State Street Corp | 3.72 | 6,694,976 | +36.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.77 | 6,785,307 | +0.6 | 07/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.